PE20090123A1 - Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo - Google Patents

Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo

Info

Publication number
PE20090123A1
PE20090123A1 PE2008001407A PE2008001407A PE20090123A1 PE 20090123 A1 PE20090123 A1 PE 20090123A1 PE 2008001407 A PE2008001407 A PE 2008001407A PE 2008001407 A PE2008001407 A PE 2008001407A PE 20090123 A1 PE20090123 A1 PE 20090123A1
Authority
PE
Peru
Prior art keywords
amino
members
active ingredient
same
methylsulfonil
Prior art date
Application number
PE2008001407A
Other languages
English (en)
Inventor
Yoshikazu Takaoka
Rena Nishizawa
Shiro Shibayama
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of PE20090123A1 publication Critical patent/PE20090123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

SE REFIERE A DERIVADOS HETEROCICLICOS DE FORMULA I, DONDE R1 ES N(R1A)SO2-R1B, -COOR1E, -OR1F, ENTRE OTROS; R1A, R1B, R1E Y R1F SON CADA UNO H, HIDROCARBURO SUSTITUIDO O NO, HETEROCICLO DE 3-15 MIEMBROS, ENTRE OTROS; X E Y SON CADA UNO UN ENLACE O ALQUILO C1-C3; A Y B SON ANILLOS QUE REPRESENTAN CADA UNO CARBOCICLICO DE 3-15 MIEMBROS, HETEROCICLO SUSTITUIDO O NO; D ES UN HETEROCICLO NITROGENADO DE 3-15 MIEMBROS SUSTITUIDO O NO; R2 ES H, HIDROCARBURO SUSTITUIDO O NO, CN, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS:2-(5-{[(BUTIL{1-[(6-{4-[(METILSULFONIL)AMINO]FENOXI}-3-PIRIDINIL)METIL]-4-PIPERIDINIL}AMINO)CARBONIL]AMINO}-2,4-DIFLUOROFENIL)ACETAMIDA; N'-(4-FLUOROFENIL)-N-[1-({6-[4-(METILSULFONIL)FENOXI]PIRIDI-3-NIL}METIL)PIPERIDI-4-NIL]-N-FENILUREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, LA CUAL PUEDE CONTENER UNO O MAS AGENTES SELECCIONADOS DE UN INHIBIDOR DE TRANSFERASA INVERSA, ANTAGONISTA CCR2, INHIBIDOR DE FUSION, INMUNOSUPRESOR, ENTRE OTROS. DICHOS COMPUESTOS SON ANTAGONISTAS DE QUIMIOCINA CCR5 Y SON UTILES EN LA PREVENCION Y/O TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, INMUNOLOGICAS, INFECCIOSAS, ALERGICAS, ENTRE OTROS
PE2008001407A 2004-09-13 2005-09-12 Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo PE20090123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004264855 2004-09-13
JP2005127359 2005-04-26

Publications (1)

Publication Number Publication Date
PE20090123A1 true PE20090123A1 (es) 2009-03-10

Family

ID=36060170

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005001056A PE20060598A1 (es) 2004-09-13 2005-09-12 Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
PE2008001407A PE20090123A1 (es) 2004-09-13 2005-09-12 Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2005001056A PE20060598A1 (es) 2004-09-13 2005-09-12 Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5

Country Status (20)

Country Link
US (3) US8143404B2 (es)
EP (2) EP2546234A1 (es)
JP (1) JP4894518B2 (es)
KR (1) KR101231466B1 (es)
CN (1) CN101775013A (es)
AR (1) AR050643A1 (es)
AU (1) AU2005283326B2 (es)
BR (1) BRPI0515164A (es)
CA (1) CA2579501C (es)
ES (1) ES2457041T3 (es)
IL (1) IL181783A (es)
MA (1) MA28921B1 (es)
MX (1) MX2007002886A (es)
NO (1) NO20071342L (es)
NZ (1) NZ553696A (es)
PE (2) PE20060598A1 (es)
RU (1) RU2409565C2 (es)
SG (1) SG146673A1 (es)
TW (1) TWI400232B (es)
WO (1) WO2006030925A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
EP2546234A1 (en) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
BRPI0622261A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
WO2007022371A2 (en) * 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
JPWO2007105637A1 (ja) * 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
PL2018380T3 (pl) 2006-05-19 2012-05-31 Abbvie Bahamas Ltd Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2009058921A1 (en) * 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
WO2009058919A1 (en) * 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
EP2268646B9 (en) 2008-04-11 2014-11-19 Janssen Pharmaceutica, N.V. Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
US8242106B2 (en) 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
AU2009292631A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
ES2705101T3 (es) 2008-11-06 2019-03-21 Ventirx Pharmaceuticals Inc Métodos de síntesis de derivados de benzazepinas
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
EP2430019B1 (en) 2009-05-14 2013-09-18 Janssen Pharmaceutica, N.V. Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
RU2016108987A (ru) 2009-08-18 2018-11-26 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
PT2467377T (pt) 2009-08-18 2017-04-04 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores de tipo toll
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JP6189874B2 (ja) 2012-03-13 2017-08-30 レスピバート・リミテツド 新規製薬学的製剤
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
ES2804271T3 (es) * 2013-05-27 2021-02-05 Hoffmann La Roche Nuevos compuestos de 3,4-dihidro-2H-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
MX2020008061A (es) 2018-01-31 2020-09-09 Janssen Sciences Ireland Unlimited Co Pirazolopirimidinas sustituidas con cicloalquilo que tienen actividad contra vrs.
WO2019206828A1 (en) 2018-04-23 2019-10-31 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against rsv
BR112021009877A2 (pt) 2018-11-22 2021-08-17 Qilu Regor Therapeutics Inc. agonistas glp-1r e usos dos mesmos
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20220073497A1 (en) * 2018-12-28 2022-03-10 Mitsubishi Tanabe Pharma Corporation Crystal of pyrrolidine compound
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1063744A (en) * 1964-05-25 1967-03-30 American Cyanamid Co 4-substituted-4'-tertiary aminoalkoxy biphenyls
US5169855A (en) 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
IL118469A (en) 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
EE9800335A (et) 1996-03-28 1999-04-15 Glaxo Group Limited Pürrolopürrolooni derivaadid kui neutrofiilelastaasi inhibiitorid
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
ES2162686T3 (es) 1996-12-19 2002-01-01 Aventis Pharma Inc Nuevos derivados carboxamidas ciclicos sustituidos por carboxi.
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6340759B1 (en) 1997-10-02 2002-01-22 Eisai Co., Ltd. Fused pyridine derivatives
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
WO1999031062A1 (fr) 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Nouveaux composes de pyridine
US6172061B1 (en) * 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
WO1999055324A1 (en) 1998-04-27 1999-11-04 Smithkline Beecham Corporation Ccr-3 receptor antagonists
US6420424B1 (en) 1998-04-27 2002-07-16 Smithkline Beecham Corporation CCR-3 receptor antagonists
WO2000006085A2 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Compounds and methods
HUP0102752A3 (en) 1998-07-28 2002-11-28 Smithkline Beecham Corp Substituted anilide compounds
JP2002521441A (ja) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Ｃｃｒ５モジュレーターとしてのプロペンアミド
CA2337307A1 (en) 1998-08-20 2000-03-02 Osamu Nishimura Quaternary ammonium salts and their use
WO2000021916A1 (fr) 1998-10-15 2000-04-20 Takeda Chemical Industries, Ltd. Procede de preparation de derives d'amine
WO2000027835A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000027843A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
PT1131291E (pt) 1998-11-17 2005-01-31 Hoffmann La Roche Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
TR200101398T2 (tr) 1998-11-20 2001-09-21 F.Hoffmann-La Roche Ag Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
DE69938193D1 (de) 1998-11-20 2008-04-03 Hoffmann La Roche Piperidin ccr-3 rezeptor-hemmer
EP1067130A4 (en) 1998-12-04 2004-02-11 Toray Industries TRIAZOLO DERIVATIVES, AND CHIMIOKIN INHIBITORS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT
WO2000035876A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140834A1 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
DE69926919D1 (de) 1998-12-18 2005-09-29 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
EP1156807A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
EP1140086A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
KR20010101287A (ko) 1998-12-18 2001-11-14 블레어 큐. 퍼거슨 케모킨 수용체 활성의 조절자로서 ｎ-우레이도알킬-피페리딘
EP1140896A1 (en) 1998-12-21 2001-10-10 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
DE69916496T2 (de) 1998-12-30 2004-09-02 Smithkline Beecham Corp. Zusammensetzung und verfahren
IL144289A0 (en) 1999-01-13 2002-05-23 Millennium Pharm Inc Functionalized heterocycles as chemokine receptor modulators
WO2000041685A1 (en) 1999-01-19 2000-07-20 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000042852A1 (en) 1999-01-25 2000-07-27 Smithkline Beecham Corporation Compounds and methods
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
JP2000309598A (ja) 1999-02-25 2000-11-07 Takeda Chem Ind Ltd 多剤結合型新規化合物、その製造法および用途
WO2000051609A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
AU3386700A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
AU3389300A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
WO2000053172A1 (en) 1999-03-08 2000-09-14 Smithkline Beecham Corporation Ccr-3 receptor antagonists
ATE270547T1 (de) 1999-03-10 2004-07-15 Smithkline Beecham Corp Substituierte benzo(1,2-b:5,4-b')dipyran-4-amine als ccr5 modulatoren
AU2942000A (en) 1999-03-11 2000-09-28 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivatives
AU775123B2 (en) 1999-03-24 2004-07-15 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
US6518286B1 (en) 1999-03-26 2003-02-11 Astrazeneca Ab Compounds
US6498161B1 (en) 1999-04-06 2002-12-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
WO2000066551A1 (fr) 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Composes d'amides cycliques, leurs procedes de preparation et d'utilisation
WO2000066112A1 (en) 1999-05-03 2000-11-09 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
HUP0202734A3 (en) 1999-05-04 2003-11-28 Schering Corp Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
WO2000066558A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
JP3894729B2 (ja) 1999-05-04 2007-03-22 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
WO2000068203A1 (fr) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Composes cycliques et leurs utilisations
AU4796700A (en) 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
ATE308985T1 (de) 1999-05-18 2005-11-15 Teijin Ltd Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
MXPA01012165A (es) 1999-05-27 2003-06-30 Celltek Biotechnologies Inc Antagonistas ccr3 del receptor de quimiocina.
US6165261A (en) 1999-06-10 2000-12-26 Ergon, Inc. Water-resistant gypsum composition
JP2003506348A (ja) 1999-07-28 2003-02-18 麒麟麦酒株式会社 Ｃｃｒ−３受容体のインヒビターとしての尿素誘導体
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
WO2001016114A2 (en) 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
FR2798367B1 (fr) * 1999-09-15 2001-11-23 Valois Sa Joint de soupape pour valve doseuse
HUP0300641A2 (hu) 1999-12-03 2003-06-28 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6894063B2 (en) 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
EP1322628A2 (en) 2000-09-14 2003-07-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
KR100883184B1 (ko) 2000-12-11 2009-02-12 암젠 인코포레이션 Ｃｘｃｒ3 길항제
GB0100102D0 (en) * 2001-01-03 2001-02-14 Syngenta Participations Ag Organic compounds
CA2440238C (en) 2001-03-16 2011-09-13 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
DE60212110T2 (de) 2001-03-19 2006-11-09 Ono Pharmaceutical Co. Ltd. Triazaspiro (5.5) undecanderivate und arzneimittel, die diese derivate als wirkstoff enthalten
PT1373256E (pt) * 2001-03-29 2005-11-30 Schering Corp Antagonistas dos ccr5 uteis para tratamento de sida
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
CA2443697A1 (en) 2001-04-13 2002-10-24 Pier F. Cirillo 1,4-disubstituted benzo-fused compounds
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6495569B1 (en) 2001-04-19 2002-12-17 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
AU2002310156A1 (en) 2001-06-05 2002-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
OA12623A (en) 2001-06-20 2006-06-12 Pfizer Prod Inc Novel sulfonic acid derivatives.
US6867221B2 (en) * 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
KR20050044417A (ko) * 2001-11-14 2005-05-12 쉐링 코포레이션 카나비노이드 수용체 리간드
TW200302717A (en) 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
EP1554253A4 (en) 2002-06-03 2006-09-20 Smithkline Beecham Corp IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
PL376154A1 (en) 2002-09-18 2005-12-27 Ono Pharmaceutical Co, Ltd. Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
WO2004041279A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
AU2003284402A1 (en) 2002-11-15 2004-06-15 Yamanouchi Pharmaceutical Co., Ltd. Antagonist to melanin-concentrating hormone receptor
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
JP2004256531A (ja) 2003-02-07 2004-09-16 Takeda Chem Ind Ltd 三環性化合物、その製造法および用途
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
CA2522431A1 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US7732442B2 (en) * 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
EP2546234A1 (en) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
JP2007063268A (ja) 2005-08-05 2007-03-15 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007022371A2 (en) 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤

Also Published As

Publication number Publication date
IL181783A0 (en) 2007-07-04
PE20060598A1 (es) 2006-08-21
IL181783A (en) 2013-02-28
ES2457041T3 (es) 2014-04-24
RU2409565C2 (ru) 2011-01-20
EP1790637A1 (en) 2007-05-30
KR101231466B1 (ko) 2013-02-07
AR050643A1 (es) 2006-11-08
US20130085275A1 (en) 2013-04-04
CA2579501C (en) 2013-09-10
US20110152520A1 (en) 2011-06-23
EP1790637B1 (en) 2014-01-29
TWI400232B (zh) 2013-07-01
WO2006030925A1 (ja) 2006-03-23
KR20070057936A (ko) 2007-06-07
JP4894518B2 (ja) 2012-03-14
CA2579501A1 (en) 2006-03-23
US8410276B2 (en) 2013-04-02
JPWO2006030925A1 (ja) 2008-05-15
EP2546234A1 (en) 2013-01-16
US20080057074A1 (en) 2008-03-06
US8143404B2 (en) 2012-03-27
MX2007002886A (es) 2007-05-16
AU2005283326A1 (en) 2006-03-23
RU2007113814A (ru) 2008-11-10
CN101775013A (zh) 2010-07-14
BRPI0515164A (pt) 2008-07-08
TW200616956A (en) 2006-06-01
MA28921B1 (fr) 2007-10-01
AU2005283326B2 (en) 2011-07-21
EP1790637A4 (en) 2010-03-24
NZ553696A (en) 2010-02-26
SG146673A1 (en) 2008-10-30
NO20071342L (no) 2007-06-13
US8604207B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
PE20090123A1 (es) Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
PE20071232A1 (es) Derivados de piperidina o piperazina como inhibidores de 11-beta hsd1
PE20051051A1 (es) Compuestos de triazol como antagonistas de la vasopresina
AR049696A1 (es) Derivados de indol
JP2006500348A5 (es)
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
PE20040647A1 (es) Inhibidores de cinasas de tirosina
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20030007A1 (es) Inhibidores de aldosa reductasa del grupo de las piridazinonas
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
KR910009705A (ko) 수용성이 개선된 이미다조[4,5-b] 퀴놀리닐 옥시알칸산 아미드
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
BR0017025A (pt) Antagonistas do receptor y5 do neuropeptìdeo y de imidazola substituìda
RU2009117469A (ru) Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
AR049699A1 (es) Derivados de pirimidina
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina

Legal Events

Date Code Title Description
FD Application declared void or lapsed